Our results show that high expression of CD109 and IL6Rα (CD109high/IL6Rαhigh versus CD109low/IL6Rαlow) correlated with worse overall and disease-free survival, suggesting that CD109 represents an important prognostic marker in HNSCC patients (Fig. 8E). This evidence concerns the gene CD109 and head and neck squamous cell carcinoma.